Previous 10 | Next 10 |
WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63 rd American Society of Hematology (ASH) Annual Meeting Key opinio...
5 Penny Stocks To Watch With Potential Catalysts It’s the weekend, and we’re nearing the end of the year. But that doesn’t mean the stock market closes anytime soon. December is always an interesting time for traders. Some are looking to cut some heavy bags and harv...
Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs i...
Mustang Bio (NASDAQ:MBIO): Q3 GAAP EPS of -$0.19 misses by $0.01. Revenue of $0M Press Release As of September 30, 2021, Mustang’s cash and cash equivalents and restricted cash totaled $121.9 million. For further details see: Mustang Bio EPS misses by $0.01
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
Agreement expands Mustang’s pipeline of lentiviral gene therapies for SCID Preclinical development of additional targets to continue at Leiden University WORCESTER, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:...
WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
Mustang Bio (NASDAQ:MBIO) has been awarded a grant of ~$2M from the National Cancer Institute of the National Institutes of Health (NIH). Shares up more than 4% premarket. The two-year grant will partially fund the company's early-stage trial of MB-106 for patients with relapsed or ...
WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...